$Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma$

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma

Abstract Objective TQB3602 is a novel orally bioavailable proteasome inhibitor. This study is the first‐in‐human phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TQB3602 in relapsed/refractory multiple myeloma (RRMM). Methods This is a multic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenjiao Tang, Yan Li, Li Zhang, Xushu Zhong, Qiushi Liang, Yuhuan Zheng, Yuzhang Liu, Yafei Wang, Xunqiang Wang, Yun Zeng, Baijun Fang, Li Zheng, Ting Niu
Format:	Article
Language:	English
Published:	Wiley 2024-07-01
Series:	Cancer Medicine
Subjects:	antitumor activity maximum tolerated dose proteasome inhibitors relapsed and refractory multiple myeloma
Online Access:	https://doi.org/10.1002/cam4.7435
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Real-World Outcomes of Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab, Pomalidomide, and Dexamethasone
by: Hitomi Nakayama, et al.
Published: (2024-09-01)

Outcomes of Ixazomib Treatment in Relapsed and Refractory Multiple Myeloma: Insights from Croatian Cooperative Group for Hematologic Diseases (KROHEM)
by: Josip Batinić, et al.
Published: (2024-11-01)

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan
by: Chieh-Lin Jerry Teng, et al.
Published: (2024-12-01)

Prevalence of measurable residual disease in patients with refractory/relapsed multiple myeloma who reached complete response: a cross-sectional multicentric study
by: Manuel Neves, et al.
Published: (2024-12-01)

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
by: Wee-Joo Chng, et al.
Published: (2024-11-01)

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects
by: Ada Alice Dona, et al.
Published: (2025-01-01)

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?
by: Davor Galusic, et al.
Published: (2025-01-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Serum indicators in functional high-risk multiple myeloma patients undertaking proteasome inhibitors therapy: a retrospective study
by: Linquan Zhan, et al.
Published: (2024-12-01)

ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF‐κB in multiple myeloma
by: Jifeng Jiang, et al.
Published: (2020-10-01)

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report
by: Reilly Fankhauser, et al.
Published: (2024-11-01)

Efficacy of Anti-CD38 Monoclonal Antibodies for Relapsed or Refractory Multiple Myeloma in Stem Cell Transplant-Ineligible Patients Aged over 65 Years: A Propensity Score-Matched Study
by: Satoshi Yamasaki, et al.
Published: (2024-11-01)

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
by: Xu Yang, et al.
Published: (2024-12-01)

Successful treatment of gastric relapse in multiple myeloma with bortezomib after autologous hematopoietic stem cell transplantation (autoHSCT)
by: Serdar Sivgin
Published: (2013-01-01)

Detection of early relapse in multiple myeloma patients
by: Tereza Růžičková, et al.
Published: (2025-01-01)

Refractory and relapsing forms of <i>Clostridium difficile</i>-associated colitis
by: A. A. Sheptulin
Published: (2011-03-01)

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
by: Eva Plakoula, et al.
Published: (2025-01-01)

Front‐line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real‐world setting: A multicenter retrospective study in China
by: Li Bao, et al.
Published: (2023-02-01)

Updates in novel immunotherapeutic strategies for relapsed/refractory AML
by: Sawyer Bawek, et al.
Published: (2024-12-01)

Combination of venetoclax and azacitidine in relapsed/refractory acute B-cell lymphoblastic leukemia: a case series from a single center
by: Ziyi Hao, et al.
Published: (2024-12-01)

The efficacy of Fludarabine, high dose cytosine arabinoside with granulocyte colony stimulating factor (FLAG) protocol as salvage therapy for Refractory/Relapsed Acute Leukemias in adult Iraqi patients.
by: Alaa Fadhil Alwan, et al.
Published: (2014-08-01)

Molecular insights into the unique properties of the blood‐circulating proteasome
by: Yegor Leushkin, et al.
Published: (2025-01-01)

Structural comparison of human and Plasmodium proteasome β5 subunits: informing selective inhibitor design for anti-malaria agents
by: Muhammad Yasir, et al.
Published: (2025-01-01)

Efficacy and safety of the combination of decitabine and CHAG priming regimen in the relapsed or refractory acute myeloid leukemia
by: Yan Wu, et al.
Published: (2024-11-01)

Dynamics of minimal residual disease and its clinical implications in multiple myeloma: A retrospective real-life analysis
by: Weiling Xu, et al.
Published: (2024-11-01)

Short‐Course Blinatumomab Treatment as a Bridge to Further Salvage Therapy for Relapsed/Refractory B‐Cell Acute Lymphoblastic Leukemia: A Retrospective Single‐Center Study
by: Jin Yin, et al.
Published: (2024-12-01)

Design and synthesis of amino-substituted N-arylpiperidinyl-based inhibitors of the (immuno)proteasome
by: Gobec Martina, et al.
Published: (2023-09-01)

Editorial: Updates on giant cell arteritis: pathogenesis, diagnosis and treatment, volume II
by: Andreas P. Diamantopoulos, et al.
Published: (2024-11-01)

Predicted indirectly recognizable HLA epitopes scores and clinical outcomes after haploidentical stem cell transplantation in pediatric patients with relapsed neuroblastoma
by: Eun Seop Seo, et al.
Published: (2025-01-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2014-08-01)

Corrigendum: Predicted indirectly recognizable HLA epitopes scores and clinical outcomes after haploidentical stem cell transplantation in pediatric patients with relapsed neuroblastoma
by: Eun Seop Seo, et al.
Published: (2025-02-01)

DL-ICE as a bridge to allogeneic transplantation in relapsed/refractory PTCL: survival outcomes and prognostic factors
by: Tong-Yoon Kim, et al.
Published: (2024-12-01)

Lamin B receptor plays a key role in cellular senescence induced by inhibition of the proteasome
by: Atsuki En, et al.
Published: (2020-02-01)

Real life clinical outcomes of relapsed/refractory diffuse large B cell lymphoma in the rituximab era: The STRIDER study
by: Irene Dogliotti, et al.
Published: (2024-07-01)

Phloem sap from melon plants contains extracellular vesicles that carry active proteasomes which increase in response to aphid infestation
by: Christian M. Sánchez‐López, et al.
Published: (2024-10-01)

A Molecular Signature of the Ubiquitin-Proteasome System for Forecasting Prognosis in Thyroid Carcinoma Patients
by: Zeng H, et al.
Published: (2024-12-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-06-01)

Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET
by: Alessandro Gozzetti, et al.
Published: (2012-01-01)

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects
by: Abdullah AlZahrani, et al.
Published: (2024-12-01)

Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia
by: Tingting Yang, et al.
Published: (2025-01-01)